Prognostic factors and outcome of Epstein–Barr virus DNAemia in high‐risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab
Authors:
- 13 February 2013
- journal article
- research article
- Published by Wiley in Transplant Infectious Disease
- Vol. 15 (3) , 259-267
Abstract
Aims and methods: This study assessed incidence, predictive factors, and outcome of Epstein–Barr virus (EBV) DNAemia in 100 recipients of allogeneic hematopoietic stem cell transplant. A total of 68 patients received anti‐thymocyte globulin before unrelated grafts.Results: Cumulative incidence of high‐load EBV DNAemia defined by levels >10,000 copies/mL was 14% at 12 months. In multivariate analysis, a CD4+ T‐lymphocyte count >50 μL at day +30 was the only factor significantly associated with a reduced risk of high‐load EBV DNAemia. Thirteen of 16 patients with high viral loads were preemptively treated with rituximab and achieved EBV DNA negativity. Three patients had already developed post‐transplant lymphoproliferative disorder (PTLD) at the time of detection of high EBV DNA loads, and they obtained complete response after rituximab infusions and chemotherapy. Patients with high EBV DNA load had a significantly higher transplant‐related mortality (TRM) compared with patients with negative or low viral load (54% vs. 16%, P = 0.009) and a trend to lower overall survival (55% vs. 29%, P = 0.060).Conclusion: We conclude that CD4+ cell count at day +30 is a predictive factor for EBV DNAemia and may help identify patients requiring closer monitoring. Although only 3% of patients progressed to PTLD and were all successfully managed, EBV reactivation was associated with higher TRM, mainly because of infections.Keywords
This publication has 30 references indexed in Scilit:
- Rituximab Treatment for Epstein-Barr Virus DNAemia after Alternative-Donor Hematopoietic Stem Cell TransplantationTransplantation and Cellular Therapy, 2011
- Strategies to Prevent EBV Reactivation and Posttransplant Lymphoproliferative Disorders (PTLD) after Allogeneic Stem Cell Transplantation in High-Risk PatientsTransplantation and Cellular Therapy, 2011
- Incidence and Dynamics of Epstein-Barr Virus Reactivation After Alemtuzumab-Based Conditioning for Allogeneic Hematopoietic Stem-Cell TransplantationTransplantation, 2010
- A Prospective Study on Modulation of Immunosuppression for Epstein-Barr Virus Reactivation in Pediatric Patients Who Underwent Unrelated Hematopoietic Stem-Cell TransplantationTransplantation, 2010
- Defining the Intensity of Conditioning Regimens: Working DefinitionsTransplantation and Cellular Therapy, 2009
- Viral-load and B-lymphocyte monitoring of EBV reactivation after allogeneic hemopoietic SCT in childrenBone Marrow Transplantation, 2009
- Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantationBlood, 2009
- Kinetics of Epstein-Barr Virus DNA Load in Different Blood Compartments of Pediatric Recipients of T-Cell-Depleted HLA-Haploidentical Stem Cell TransplantationJournal of Clinical Microbiology, 2008
- Antithymocyte Globulin Pharmacokinetics in Pediatric Patients After Hematopoietic Stem Cell TransplantationJournal of Pediatric Hematology/Oncology, 2005
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999